Standard Biotools
Standard Biotools' revenue fell 6.2% to $85 million in fiscal 2025. Its operating margin was −129.2%, up from −140.1% a year earlier. Free cash flow was −$83 million. The diluted share count rose 8.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Standard Biotools lost money in fiscal 2025: a net loss of $75 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 30 | 167 | 115 | 293 | 188 |
| Debt incl. finance leases | 54 | 65 | 64 | 0 | 0 |
| Net debt (negative means net cash) | 25 | −102 | −51 | −293 | −187 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.6x | — | — | 0.0x | 0.0x |
| Interest coverage | −17.6x | −26.8x | −16.8x | −41.3x | −7,349.9x |
| Current ratio | 1.4x | 4.8x | 1.4x | 5.7x | 4.2x |
| Quick ratio | 1.0x | 4.3x | 1.3x | 5.4x | 4.0x |
Cash flow
Projections
Project Standard Biotools' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $11.1 million of Standard Biotools shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | Casdin Private Growth Equity Fund Gp LlcDirector | Bought | 150,000 | $1.45 | $217,500 | Form 4 |
| Dec 3, 2025 | Casdin Private Growth Equity Fund Gp LlcDirector | Bought | 75,000 | $1.44 | $108,000 | Form 4 |
| Dec 2, 2025 | Casdin Private Growth Equity Fund Gp LlcDirector | Bought | 125,000 | $1.42 | $177,500 | Form 4 |
| Nov 25, 2025 | Casdin Partners GP LLCDirector, 10% owner | Bought | 7,550,000 | $1.30 | $9.8 million | Form 4 |
| Nov 24, 2025 | Casdin Partners GP LLCDirector, 10% owner | Bought | 150,000 | $1.43 | $214,500 | Form 4 |
| Nov 20, 2025 | Eli CasdinDirector, 10% owner | Bought | 450,000 | $1.30 | $585,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | −34.8% | −181.2% | −103.1% |
| Altman Z'' | −11.67 | −0.87 | −1.44 |
| Accruals ratio | −8.8% | 1.0% | −0.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 4 of 9 | 4 of 9 | 4 of 9 |
Compare
Put Standard Biotools side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Standard Biotools | FY25 | −6.2% | −129.2% | −96.8% | −41.9% | — | 4 | |
| Harvard Bioscience | FY25 | −8.1% | −56.1% | 6.3% | −56.0% | — | 3 | Compare |
| Codexis | FY25 | 18.6% | −59.3% | −33.9% | −189.5% | — | 4 | Compare |
| Personalis | FY25 | −17.7% | −126.4% | −114.1% | — | — | — | Compare |
| Quanterix | FY25 | 1.1% | −90.4% | −57.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 104 | 102 | 113 | 117 | 138 | 131 | 98 | 106 | 91 | 85 |
| Revenue growth | −8.9% | −2.4% | 10.8% | 3.8% | 17.8% | −5.5% | −25.0% | 8.6% | −14.4% | −6.2% |
| Gross profit | 58 | 52 | 62 | 64 | — | — | 37 | 50 | 45 | 42 |
| Research and development | 38 | 31 | 30 | 32 | 36 | 38 | 37 | 26 | 29 | 26 |
| Operating income | −73 | −58 | −48 | −52 | −51 | −68 | −116 | −77 | −128 | −110 |
| Net income | −76 | −60 | −59 | −65 | −53 | −59 | −190 | −75 | −139 | −75 |
| Diluted EPS (US$) | −2.62 | −1.84 | −1.49 | −0.97 | −0.74 | −0.78 | −2.43 | −0.94 | −0.52 | −0.20 |
| Diluted shares (millions) | 29 | 33 | 40 | 67 | 72 | 76 | 78 | 79 | 353 | 382 |
| Cash flow | ||||||||||
| Cash from operations | −39 | −24 | −25 | −35 | −15 | −44 | −89 | −43 | −144 | −74 |
| Capital expenditure | 5 | 2 | 0 | 2 | 13 | 13 | 4 | 3 | 8 | 8 |
| Free cash flow | −44 | −26 | −26 | −38 | −28 | −57 | −93 | −46 | −152 | −83 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 40 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 0 |
| Stock-based compensation | 14 | 9 | 11 | 11 | 14 | 16 | 15 | 13 | 32 | 30 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 59 | 63 | 95 | 61 | 70 | 30 | 167 | 115 | 293 | 188 |
| Debt incl. finance leases | 195 | 195 | 172 | 54 | 54 | 54 | 65 | 64 | 0 | 0 |
| Total assets | 306 | 287 | 304 | 265 | 325 | 275 | 390 | 323 | 612 | 568 |
| Total liabilities | 253 | 256 | 232 | 111 | 186 | 181 | 160 | 160 | 141 | 144 |
| Shareholders' equity | 53 | 31 | 72 | 154 | 139 | 95 | −82 | −148 | 472 | 424 |
| Margins and ratios | ||||||||||
| Gross margin | 56.0% | 51.0% | 54.6% | 54.8% | — | — | 37.8% | 47.4% | 49.3% | 49.9% |
| Operating margin | −70.1% | −57.2% | −42.6% | −44.2% | −36.9% | −51.7% | −118.6% | −72.0% | −140.1% | −129.2% |
| Net margin | −72.8% | −59.4% | −52.2% | −55.3% | −38.4% | −45.4% | −194.1% | −70.2% | −152.6% | −87.8% |
| Free cash flow margin | −42.3% | −25.2% | −22.6% | −32.2% | −20.4% | −43.9% | −95.2% | −43.4% | −166.8% | −96.8% |
| Rule of 40 (growth + FCF margin) | −51.3% | −27.6% | −11.8% | −28.4% | −2.5% | −49.4% | −120.1% | −34.8% | −181.2% | −103.1% |
| Return on capital | −28.7% | −26.2% | −24.4% | −27.7% | −29.8% | −43.9% | — | — | — | −41.9% |
| Return on equity | −90.4% | −143.8% | −114.5% | −57.4% | −36.2% | −50.7% | — | — | −85.8% | −16.7% |
| Return on assets | −22.5% | −20.4% | −20.0% | −22.8% | −18.0% | −19.8% | −57.1% | −20.9% | −29.7% | −12.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |